Effect of Nano-magnesium Oxide on Glucose Concentration and Lipid Profile in Diabetic Laboratory Mice Effect of nano-magnesium oxide on diabetic mouse
Iranian Journal of Pharmaceutical Sciences,
Vol. 10 No. 3 (2014),
1 July 2014
,
Page 63-68
https://doi.org/10.22037/ijps.v10.40817
Abstract
https://doi.org/10.22034/IJPS.2014.15248
Nano-sized drugs have better distribution than their identical forms. Magnesium is the cofactor of various enzymes in lipid and glucose metabolism. In this study, the effect of nano-magnesium oxide (nano-MgO) on glucose concentration and lipid profile in diabetes induced mice was evaluated in 21 laboratory mice. Mice were randomly divided into three equal groups (control, treatment, and placebo). Diabetes was induced in treatment and placebo group by injection of 60 mg/kg streptozotocin while control group was injected by saline. Treatment group was injected by 2 mg/kg of nano-MgO every 48 hours until the day 45. Serum glucose was measured at 3, 46, and 48 days. Concentration of triglyceride (TG), cholesterol, high density lipoprotein (HDL) and low density lipoprotein (LDL) was measured at day 48. Treatment and placebo group had higher glucose level at day 3 but treatment group at days 46 and 48 had lower glucose levels than placebo group. Diabetic mice had higher levels of TG, cholesterol, LDL and lower levels of HDL than control group in their serum samples. Treatment with MgO ameliorated change in glucose, TG, HDL and LDL level in treated mice. Our study has showed that administration of nano-MgO decreased glucose concentration and ameliorated TG, HDL and LDL levels in diabetes induced mice.
- Diabetes
- glucose
- lipid profile
- nano drug
- nano-magnesium oxide
How to Cite
References
[2] de Lordes Lima, M, Cruz, T, Pousada, JC, Rodrigues, LE, Barbosa, K, Cangucu, V. The effect of magnesium supplementation in increasing doses on the control of type 2 diabetes. Diabetes Care (1998)21(5): 682-686.
[3] Mooradian, AD, Failla, M, Hoogwerf, B, Maryniuk, M, Wylie-Rosett, J. Selected vitamins and minerals in diabetes. Diabetes Care (1994)17(5): 464-479.
[4] Tosiello, L. Hypomagnesemia and diabetes mellitus. A review of clinical implications. Arch Intern Med (1996)156(11): 1143-1148.
[5] Olatunji, LA, Soladoye, AO. Increased magnesium intake prevents hyperlipidemia and insulin resistance and reduces lipid peroxidation in fructose-fed rats. Pathophysiology (2007)14(1): 11-15.
[6] Dasgupta, A, Sarma, D, Saikia, UK. Hypomagnesemia in type 2 diabetes mellitus. Indian J Endocrinol Metab (2012)16(6): 1000-1003.
[7] Alzaid, AA, Dinneen, SF, Moyer, TP, Rizza, RA. Effects of insulin on plasma magnesium in noninsulin-dependent diabetes mellitus: evidence for insulin resistance. J Clin Endocrinol Metab (1995)80(4): 1376-1381.
[8] Guerrero-Romero, F, Rodriguez-Moran, M. Complementary therapies for diabetes: the case for chromium, magnesium, and antioxidants. Arch Med Res (2005)36(3): 250-257.
[9] Huang, L, Li, DQ, Lin, YJ, Wei, M, Evans, DG, Duan, X. Controllable preparation of Nano-MgO and investigation of its bactericidal properties. J Inorg Biochem (2005)99(5): 986-993.
[10] Bucolo, G, David, H. Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem (1973)19(5): 476-482.
[11] Fossati, P, Prencipe, L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem (1982)28(10): 2077-2080.
[12] Allain, CC, Poon, LS, Chan, CS, Richmond, W, Fu, PC. Enzymatic determination of total serum cholesterol. Clin Chem (1974)20(4): 470-475.
[13] Pelliniemi, TT, Viikari, J, Nieminen, L. Effect of hyperlipidaemic diet and clofibrate treatment on rat erythrocyte lipids. Scand J Haematol (1976)17(2): 117-122.
[14] Demacker, PN, Hijmans, AG, Vos-Janssen, HE, van't Laar, A, Jansen, AP. A study of the use of polyethylene glycol in estimating cholesterol in high-density lipoprotein. Clin Chem (1980)26(13): 1775-1779.
[15] Widhalm, K, Pakosta, R. Precipitation with polyethylene glycol and density-gradient ultracentrifugation compared for determining high-density lipoprotein subclasses HDL2 and HDL3. Clin Chem (1991)37(2): 238-240.
[16] Rifai, N, Iannotti, E, DeAngelis, K, Law, T. Analytical and clinical performance of a homogeneous enzymatic LDL-cholesterol assay compared with the ultracentrifugation-dextran sulfate-Mg2+ method. Clin Chem (1998)44(6 Pt 1): 1242-1250.
[17] Rodriguez-Moran, M, Guerrero-Romero, F. Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects: a randomized double-blind controlled trial. Diabetes Care (2003)26(4): 1147-1152.
[18] Paolisso, G, Sgambato, S, Gambardella, A, Pizza, G, Tesauro, P, Varricchio, M, D'Onofrio, F. Daily magnesium supplements improve glucose handling in elderly subjects. Am J Clin Nutr (1992)55(6): 1161-1167.
[19]Yokota, K, et al. Clinical efficacy of magnesium supplementation in patients with type 2 diabetes. J Am Coll Nutr (2004)23(5): 506S-509S.
[20] Paolisso, G, Scheen, A, Cozzolino, D, Di Maro, G, Varricchio, M, D'Onofrio, F, Lefebvre, PJ. Changes in glucose turnover parameters and improvement of glucose oxidation after 4-week magnesium administration in elderly noninsulin-dependent (type II) diabetic patients. J Clin Endocrinol Metab (1994)78(6): 1510-1514.
[21] Eibl, NL, Kopp, HP, Nowak, HR, Schnack, CJ, Hopmeier, PG, Schernthaner, G. Hypomagnesemia in type II diabetes: effect of a 3-month replacement therapy. Diabetes Care (1995)18(2): 188-192.
[22] de Valk, HW, Verkaaik, R, van Rijn, HJ, Geerdink, RA, Struyvenberg, A. Oral magnesium supplementation in insulin-requiring Type 2 diabetic patients. Diabet Med (1998)15(6): 503-507.
[23] Gullestad, L, Jacobsen, T, Dolva, LO. Effect of magnesium treatment on glycemic control and metabolic parameters in NIDDM patients. Diabetes Care (1994)17(5): 460-461.
[24] Zhu, MT, et al. Comparative study of pulmonary responses to nano- and submicron-sized ferric oxide in rats. Toxicology (2008)247(2-3): 102-111.
[25] Limbach, LK, Wick, P, Manser, P, Grass, RN, Bruinink, A, Stark, WJ. Exposure of engineered nanoparticles to human lung epithelial cells: influence of chemical composition and catalytic activity on oxidative stress. Environ Sci Technol (2007)41(11): 4158-4163.
[26] Odonkor, JM, Rogers, MP. Effects of ethyl-CPIB (clofibrate) on tissue lipoprotein lipase and plasma post-heparin lipolytic activity in rats. Biochem Pharmacol (1984)33(8): 1337-1341.
[27] Langer, R, Cleland, JL, Hanes, J. New advances in microsphere-based single-dose vaccines. Adv Drug Deliv Rev (1997)28(1): 97-119.
[28] Torres-Martinez, CL, Kho, R, Mian, OI, Mehra, RK. Efficient Photocatalytic Degradation of Environmental Pollutants with Mass-Produced ZnS Nanocrystals. J Colloid Interface Sci (2001)240(2): 525-532.
[29] Renwick, LC, Donaldson, K, Clouter, A. Impairment of alveolar macrophage phagocytosis by ultrafine particles. Toxicol Appl Pharmacol (2001)172(2): 119-127.
[30] Hoet, PH, Bruske-Hohlfeld, I, Salata, OV. Nanoparticles - known and unknown health risks. J Nanobiotechnology (2004)2(1): 12.
- Abstract Viewed: 103 times
- IJPS_Volume 10_Issue 3_Pages 63-68 Downloaded: 37 times